BIIB

Business Context and Reporting Period

Company: Biogen Idec Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2006
Business Overview: Biogen Idec is a global biotechnology company focused on oncology, neurology, and immunology. Key products include AVONEX (multiple sclerosis), RITUXAN (oncology/rheumatoid arthritis), TYSABRI (multiple sclerosis), FUMADERM (psoriasis), and ZEVALIN (oncology). The period was marked by the reintroduction of TYSABRI following a 2005 suspension and significant strategic acquisitions.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 18.0% for the three months and 10.3% for the nine months compared to the prior year periods. This was driven by AVONEX sales growth and the resumption of TYSABRI sales in Q3 2006.
• Profitability Surge: Net income for the three months ended September 30, 2006, jumped to $156.6 million from $27.2 million in the prior year. This increase was significantly aided by a $34.2 million gain on the settlement of a license agreement related to the Fumapharm acquisition and lower facility impairment charges compared to 2005.
• Acquisition Charges: The nine-month period included $330.5 million in non-cash expenses for Acquired In-Process Research and Development (IPR&D) related to the acquisitions of Fumapharm ($207.4 million) and Conforma ($123.1 million).
• Product Mix: AVONEX remained the dominant revenue driver (94% of product revenue in Q3). TYSABRI generated $18.7 million in revenue in Q3 2006 after being suspended in 2005. AMEVIVE revenue declined sharply following the sale of worldwide rights in April 2006.

Guidance, Outlook, and Risks

• TYSABRI Reintroduction: TYSABRI was reintroduced in the U.S. and Europe in mid-2006 following FDA and EMEA approvals. Management expects higher margins in the near term as previously expensed inventory is sold. However, the product carries significant safety risks (PML) and is subject to strict distribution controls (TOUCH Prescribing Program).
• Acquisitions & Pipeline: The company is investing heavily in external growth, including the Fumapharm (BG-12 for MS) and Conforma (oncology) acquisitions. New collaborations were announced with mondo, Alnylam, and UCB, involving upfront payments totaling $42.5 million.
• Accounting Changes: The company adopted SFAS 123(R) effective January 1, 2006, resulting in increased share-based compensation expenses ($102.1 million for the nine months ended Sep 30, 2006).
• Legal & Regulatory Risks:
  • Litigation: The company faces class action lawsuits regarding the TYSABRI suspension and securities laws, as well as investigations by the SEC and DOJ regarding RITUXAN marketing practices.
  • Tax Contingency: A $38.9 million tax assessment from the Massachusetts Department of Revenue for 2001-2003 is being vigorously contested.
  • Product Concentration: Revenues rely heavily on AVONEX and RITUXAN (approx. 92% of total revenue in Q3 2006).

Investor Verification Checklist

• TYSABRI Commercialization: Verify the rate of market acceptance and sell-through data for TYSABRI given the strict safety protocols and PML risks.
• Acquisition Integration: Monitor the progress of BG-12 (Fumapharm) and Conforma assets, specifically the timeline for Phase II/III trials and potential regulatory hurdles.
• Legal Exposure: Track the status of the Massachusetts tax assessment and the outcome of the TYSABRI-related securities litigation and DOJ investigations.
• Inventory Valuation: Review the valuation of TYSABRI inventory, noting that $40.6 million of previously expensed product is available for future sales, which will impact future cost of goods sold and margins.
• Share-Based Compensation: Assess the ongoing impact of SFAS 123(R) on future operating expenses and net income.